propranolol has been researched along with Cancer of Head in 39 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain." | 9.22 | Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016) |
| "Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas." | 9.14 | Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. ( Buckmiller, LM; Dai, Y; Dyamenahalli, U; Munson, PD; Richter, GT, 2010) |
| "There is the obtain that propranolol will detach steroids in the therapy for infantile haemangiomas." | 8.86 | Propranolol therapy for infantile haemangiomas: review of the literature. ( Eivazi, B; Werner, JA; Wiegand, S; Zimmermann, AP, 2010) |
| "Research regarding propranolol is in its infancy but, should the initial results and safety record be borne out, it is likely to revolutionize how we manage infantile hemangiomas." | 8.85 | Propranolol treatment for infantile hemangiomas. ( Buckmiller, LM, 2009) |
| "Despite the increasing popularity of propranolol for treatment of infantile hemangioma (IH), there is need for further evidence of efficacy and safety." | 7.83 | Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. ( Gehris, R; Geisler, S; Grunwaldt, LJ; MacIsaac, ZM; Mehta, D; Nayar, HS, 2016) |
| " The 31 patients had 32 hemangiomas (1 female patient had 2 lesions) and were treated with systemic propranolol at a high dose of 2 mg/kg per day." | 7.83 | Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases. ( Liu, ZM; Tian, Y; Tong, S; Wang, XK; Xi, SL; Xu, DP, 2016) |
| "We investigated the clinical efficacy of propranolol in treating proliferating infantile haemangiomas, and the serological changes in vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) during treatment." | 7.79 | Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. ( Jin, ZL; Liu, ZY; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2013) |
| "Propranolol is a commonly used medication for the treatment of infantile hemangiomas among otolaryngologists in the Vascular Anomalies Task Force." | 7.79 | Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. ( Darrow, DH; Grimmer, JF; Manning, SC; Parikh, SR; Perkins, JA; Richter, GT, 2013) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 7.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| "Although propranolol can be an effective primary medical therapy for infantile hemangiomas of the head and neck, the duration of treatment and time to discontinue propranolol is unclear." | 7.79 | Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age. ( Chiu, ES; Hong, P; Kluka, EA; Poole, JC; Simon, LM; Tammareddi, N; Walvekar, R, 2013) |
| "Thirty-seven infants with propranolol-treated problematic head and neck hemangiomas were included and all patients had a good response." | 7.78 | Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. ( Fan, XD; Lv, MM; Su, LX, 2012) |
| "Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up." | 7.78 | Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012) |
| "In most children with infantile hemangiomas, propranolol therapy can be safely initiated as an outpatient." | 7.77 | Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. ( Boucek, RJ; Cushing, SL; Manning, SC; Perkins, JA; Sidbury, R, 2011) |
| "Propranolol is an effective treatment of head and neck infantile hemangiomas, especially when started early within the rapid growth phase, and is first-line treatment of orbit and larynx hemangiomas." | 7.77 | Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011) |
| "Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre." | 7.77 | Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011) |
| "Oral propranolol is a very recent therapeutic option for complicated IH with impressive efficacy and generally good tolerance." | 6.46 | Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. ( Hoeger, PH; Storch, CH, 2010) |
| "Propranolol has been demonstrated to be effective for IHs; however, the factors affecting its therapeutic effect remain unknown." | 5.46 | Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. ( Dong, JY; Huang, YY; Li, K; Li, RH; Liu, C; Liu, SH; Ning, JX; Wang, XX; Yue, LL, 2017) |
| "Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension." | 5.42 | Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015) |
| " The dosage of Propranolol was increased over the course of treatment, which initiated three days." | 5.42 | Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases. ( Jianguo, K; Mingkun, Z; Qiaoling, C; Wenjin, L; Xichun, W, 2015) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 5.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 5.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain." | 5.22 | Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016) |
| "Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas." | 5.14 | Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. ( Buckmiller, LM; Dai, Y; Dyamenahalli, U; Munson, PD; Richter, GT, 2010) |
| "There is the obtain that propranolol will detach steroids in the therapy for infantile haemangiomas." | 4.86 | Propranolol therapy for infantile haemangiomas: review of the literature. ( Eivazi, B; Werner, JA; Wiegand, S; Zimmermann, AP, 2010) |
| "Research regarding propranolol is in its infancy but, should the initial results and safety record be borne out, it is likely to revolutionize how we manage infantile hemangiomas." | 4.85 | Propranolol treatment for infantile hemangiomas. ( Buckmiller, LM, 2009) |
| " The 31 patients had 32 hemangiomas (1 female patient had 2 lesions) and were treated with systemic propranolol at a high dose of 2 mg/kg per day." | 3.83 | Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases. ( Liu, ZM; Tian, Y; Tong, S; Wang, XK; Xi, SL; Xu, DP, 2016) |
| "Despite the increasing popularity of propranolol for treatment of infantile hemangioma (IH), there is need for further evidence of efficacy and safety." | 3.83 | Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. ( Gehris, R; Geisler, S; Grunwaldt, LJ; MacIsaac, ZM; Mehta, D; Nayar, HS, 2016) |
| "Intralesional compound betamethasone preparation is a feasible choice for the small-size hemangioma." | 3.81 | Intralesional injection of diprospan is effective for infantile hemangioma. ( Cui, L; Guo, Y; Hong, ZJ; Jiang, HQ; Yuan, SM; Zhang, M, 2015) |
| "Although propranolol can be an effective primary medical therapy for infantile hemangiomas of the head and neck, the duration of treatment and time to discontinue propranolol is unclear." | 3.79 | Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age. ( Chiu, ES; Hong, P; Kluka, EA; Poole, JC; Simon, LM; Tammareddi, N; Walvekar, R, 2013) |
| "Propranolol is a commonly used medication for the treatment of infantile hemangiomas among otolaryngologists in the Vascular Anomalies Task Force." | 3.79 | Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. ( Darrow, DH; Grimmer, JF; Manning, SC; Parikh, SR; Perkins, JA; Richter, GT, 2013) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 3.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| "We investigated the clinical efficacy of propranolol in treating proliferating infantile haemangiomas, and the serological changes in vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) during treatment." | 3.79 | Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. ( Jin, ZL; Liu, ZY; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2013) |
| "Thirty-seven infants with propranolol-treated problematic head and neck hemangiomas were included and all patients had a good response." | 3.78 | Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. ( Fan, XD; Lv, MM; Su, LX, 2012) |
| "Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up." | 3.78 | Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012) |
| "In most children with infantile hemangiomas, propranolol therapy can be safely initiated as an outpatient." | 3.77 | Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. ( Boucek, RJ; Cushing, SL; Manning, SC; Perkins, JA; Sidbury, R, 2011) |
| "Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers." | 3.77 | β-blockers for infantile hemangiomas: a single-institution experience. ( Blatt, J; Buck, S; Burkhart, CN; Gold, S; Morrell, DS; Powell, C; Stavas, J; Zdanski, C, 2011) |
| "Propranolol is an effective treatment of head and neck infantile hemangiomas, especially when started early within the rapid growth phase, and is first-line treatment of orbit and larynx hemangiomas." | 3.77 | Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011) |
| "Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre." | 3.77 | Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011) |
| "Infantile hemangiomas are common; but they are extremely heterogeneous and cause a range of complications depending on their morphology, size, or location." | 2.58 | Infantile Hemangiomas in the Head and Neck Region. ( Adams, DM; Ricci, KW, 2018) |
| "Propranolol has become an effective first-line treatment, and protocols for its use as well as its potential risks are outlined." | 2.48 | Current management of infantile hemangiomas and their common associated conditions. ( Buckmiller, LM; Hartzell, LD, 2012) |
| "Oral propranolol is a very recent therapeutic option for complicated IH with impressive efficacy and generally good tolerance." | 2.46 | Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. ( Hoeger, PH; Storch, CH, 2010) |
| "Propranolol has been demonstrated to be effective for IHs; however, the factors affecting its therapeutic effect remain unknown." | 1.46 | Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. ( Dong, JY; Huang, YY; Li, K; Li, RH; Liu, C; Liu, SH; Ning, JX; Wang, XX; Yue, LL, 2017) |
| "Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension." | 1.42 | Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015) |
| " The dosage of Propranolol was increased over the course of treatment, which initiated three days." | 1.42 | Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases. ( Jianguo, K; Mingkun, Z; Qiaoling, C; Wenjin, L; Xichun, W, 2015) |
| "Propranolol treatment also enhanced the effects of γ-irradiation on cell viability." | 1.38 | Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma. ( Enepekides, DJ; Irwin, MS; Wolter, JK; Wolter, NE, 2012) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 1.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 1.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.56) | 29.6817 |
| 2010's | 36 (92.31) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, JY | 1 |
| Ning, JX | 1 |
| Li, K | 1 |
| Liu, C | 2 |
| Wang, XX | 1 |
| Li, RH | 1 |
| Yue, LL | 1 |
| Huang, YY | 1 |
| Liu, SH | 1 |
| Adams, DM | 1 |
| Ricci, KW | 1 |
| Espinel, AG | 1 |
| Bauman, NM | 1 |
| Parikh, SR | 1 |
| Darrow, DH | 1 |
| Grimmer, JF | 1 |
| Manning, SC | 2 |
| Richter, GT | 3 |
| Perkins, JA | 2 |
| Ahogo, CK | 1 |
| Ezzedine, K | 2 |
| Prey, S | 1 |
| Colona, V | 1 |
| Diallo, A | 1 |
| Boralevi, F | 1 |
| Taïeb, A | 1 |
| Léauté-Labrèze, C | 3 |
| Mendiratta, V | 1 |
| Varghese, B | 1 |
| Chander, R | 1 |
| Parakh, A | 1 |
| Solanki, RS | 1 |
| Hong, P | 1 |
| Tammareddi, N | 1 |
| Walvekar, R | 1 |
| Chiu, ES | 1 |
| Poole, JC | 1 |
| Kluka, EA | 1 |
| Simon, LM | 1 |
| Huoh, KC | 1 |
| Rosbe, KW | 1 |
| Rössler, J | 1 |
| Braunschweiger, F | 1 |
| Schill, T | 1 |
| Hoff, SR | 1 |
| Rastatter, JC | 1 |
| Su, L | 1 |
| Wang, D | 1 |
| Fan, X | 1 |
| Gnarra, M | 1 |
| Solman, L | 1 |
| Harper, J | 1 |
| Batul Syed, S | 1 |
| Yuan, SM | 1 |
| Zhang, M | 1 |
| Guo, Y | 1 |
| Cui, L | 1 |
| Hong, ZJ | 1 |
| Jiang, HQ | 1 |
| Jianguo, K | 1 |
| Xichun, W | 1 |
| Mingkun, Z | 1 |
| Qiaoling, C | 1 |
| Wenjin, L | 1 |
| Tiwari, P | 1 |
| Pandey, V | 1 |
| Gangopadhyay, AN | 1 |
| Sharma, SP | 1 |
| Gupta, DK | 1 |
| MacIsaac, ZM | 1 |
| Nayar, HS | 1 |
| Gehris, R | 1 |
| Mehta, D | 1 |
| Geisler, S | 1 |
| Grunwaldt, LJ | 1 |
| Tian, Y | 1 |
| Xu, DP | 1 |
| Tong, S | 1 |
| Xi, SL | 1 |
| Liu, ZM | 1 |
| Wang, XK | 2 |
| Ren, W | 1 |
| Li, S | 1 |
| Gao, L | 1 |
| Huang, S | 1 |
| Zhang, L | 1 |
| Qiang, C | 1 |
| Zhi, K | 1 |
| Buckmiller, LM | 3 |
| Munson, PD | 1 |
| Dyamenahalli, U | 1 |
| Dai, Y | 1 |
| Zimmermann, AP | 1 |
| Wiegand, S | 1 |
| Werner, JA | 1 |
| Eivazi, B | 1 |
| Storch, CH | 1 |
| Hoeger, PH | 1 |
| Hermans, DJ | 1 |
| van Beynum, IM | 1 |
| Schultze Kool, LJ | 1 |
| van de Kerkhof, PC | 1 |
| Wijnen, MH | 1 |
| van der Vleuten, CJ | 1 |
| Saint-Jean, M | 1 |
| Mazereeuw-Hautier, J | 1 |
| Bodak, N | 1 |
| Hamel-Teillac, D | 1 |
| Kupfer-Bessaguet, I | 1 |
| Lacour, JP | 1 |
| Naouri, M | 1 |
| Vabres, P | 1 |
| Hadj-Rabia, S | 1 |
| Nguyen, JM | 1 |
| Stalder, JF | 1 |
| Barbarot, S | 1 |
| Cushing, SL | 1 |
| Boucek, RJ | 1 |
| Sidbury, R | 1 |
| Blatt, J | 1 |
| Morrell, DS | 1 |
| Buck, S | 1 |
| Zdanski, C | 1 |
| Gold, S | 1 |
| Stavas, J | 1 |
| Powell, C | 1 |
| Burkhart, CN | 1 |
| Fuchsmann, C | 1 |
| Quintal, MC | 1 |
| Giguere, C | 1 |
| Ayari-Khalfallah, S | 1 |
| Guibaud, L | 1 |
| Powell, J | 1 |
| McCone, C | 1 |
| Froehlich, P | 1 |
| Goswamy, J | 1 |
| Rothera, MP | 1 |
| Bruce, IA | 1 |
| Lv, MM | 1 |
| Fan, XD | 1 |
| Su, LX | 1 |
| Hartzell, LD | 1 |
| Pope, E | 1 |
| Chakkittakandiyil, A | 1 |
| Lara-Corrales, I | 1 |
| Maki, E | 1 |
| Weinstein, M | 1 |
| Hadaschik, E | 1 |
| Scheiba, N | 1 |
| Engstner, M | 1 |
| Flux, K | 1 |
| Hirahara, S | 1 |
| Matsuda, K | 1 |
| Toyama, K | 1 |
| Nagano, Y | 1 |
| Nagai, N | 1 |
| Tono, T | 1 |
| Katona, G | 1 |
| Csákányi, Z | 1 |
| Gács, E | 1 |
| Szalai, Z | 1 |
| Ráth, G | 1 |
| Gerlinger, I | 1 |
| Wolter, NE | 1 |
| Wolter, JK | 1 |
| Enepekides, DJ | 1 |
| Irwin, MS | 1 |
| Yuan, WL | 1 |
| Jin, ZL | 1 |
| Wei, JJ | 1 |
| Liu, ZY | 1 |
| Xue, L | 1 |
| Dumas de la Roque, E | 1 |
| Nacka, F | 1 |
| Abouelfath, A | 1 |
| Grenier, N | 1 |
| Rebola, M | 1 |
| Moore, N | 1 |
| Clarke, AD | 1 |
| Matheson, H | 1 |
| Boddie, HG | 1 |
| Bijman, JT | 1 |
| Wagener, DJ | 1 |
| van Rennes, H | 1 |
| Wessels, JM | 1 |
| Ramaekers, FC | 1 |
| van den Broek, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045] | Phase 2 | 50 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| "'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study[NCT02012777] | Phase 1 | 9 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to Inability to recruit patients into the study.) | ||
| A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)[NCT01074437] | Phase 2 | 9 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242] | Phase 2 | 22 participants (Actual) | Interventional | 2015-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | percentage of volume (Mean) |
|---|---|
| Double-Blind Placebo | 5.89 |
| Open-Label Sildenafil | -8.54 |
| Double-blind Sildenafil | -0.642 |
"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| No improvement | Minimal improvement | Fair improvement | Good improvement | Excellent improvement | |
| Double-Blind Placebo | 1 | 2 | 0 | 2 | 0 |
| Double-Blind Sildenafil | 2 | 4 | 1 | 1 | 0 |
8 reviews available for propranolol and Cancer of Head
| Article | Year |
|---|---|
Infantile Hemangiomas in the Head and Neck Region.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Head and Neck Neoplasms; Hemangioma; Humans; Infa | 2018 |
Psychosocial Impact of Vascular Anomalies on Children and Their Families.
Topics: Adaptation, Psychological; Adult; Arteriovenous Malformations; Child; Head and Neck Neoplasms; Heman | 2018 |
Infantile hemangiomas of the head and neck.
Topics: Diagnostic Imaging; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Propranolol; Vasodilator Ag | 2013 |
Head and neck vascular lesions.
Topics: Arteriovenous Malformations; Biopsy, Needle; Child; Child, Preschool; Female; Follow-Up Studies; Hea | 2015 |
Propranolol treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Propranolol | 2009 |
Propranolol therapy for infantile haemangiomas: review of the literature.
Topics: Adrenergic beta-Antagonists; Apoptosis; Down-Regulation; Endothelial Cells; Fibroblast Growth Factor | 2010 |
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Female; Fibroblast Growth Factors; | 2010 |
Current management of infantile hemangiomas and their common associated conditions.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Antiviral Agents; Bronchoscopy; Cong | 2012 |
3 trials available for propranolol and Cancer of Head
| Article | Year |
|---|---|
Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study.
Topics: Acetaminophen; Administration, Oral; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hem | 2016 |
Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Arkansas; Child, Preschool; Dose-Response Relatio | 2010 |
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age.
Topics: Antineoplastic Agents; Cicatrix; Double-Blind Method; Female; Head and Neck Neoplasms; Hemangioma; H | 2013 |
28 other studies available for propranolol and Cancer of Head
| Article | Year |
|---|---|
Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck.
Topics: Administration, Oral; Antineoplastic Agents; Female; Head and Neck Neoplasms; Hemangioma; Humans; In | 2017 |
Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns.
Topics: Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Drug A | 2013 |
Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
Topics: Administration, Oral; Antineoplastic Agents; Child; Child, Preschool; Female; Head and Neck Neoplasm | 2013 |
Successful management of airway hemangioma with propranolol.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Epiglottis; Female; Head and Neck Neoplasms; Hemang | 2013 |
Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age.
Topics: Adrenergic beta-Antagonists; Age Factors; Female; Follow-Up Studies; Head and Neck Neoplasms; Hemang | 2013 |
[Medication-based therapy of infantile hemangioma and lymphatic malformations].
Topics: Antibiotics, Antineoplastic; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Infant, Ne | 2014 |
Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region.
Topics: Blood Coagulation Tests; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow-Up Stu | 2015 |
Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Antineoplastic Agents, Hormonal; Blepharoptosi | 2015 |
Intralesional injection of diprospan is effective for infantile hemangioma.
Topics: Betamethasone; Drug Combinations; Female; Follow-Up Studies; Glucocorticoids; Head and Neck Neoplasm | 2015 |
Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases.
Topics: Antineoplastic Agents; Blood Glucose; Blood Pressure; Drug Administration Schedule; Facial Neoplasms | 2015 |
Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antineoplastic Agents; Body Weight; Cohort Studie | 2016 |
Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases.
Topics: Administration, Oral; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; | 2016 |
Low-dose propranolol for infantile hemangioma of the head and neck: Analysis of 23 consecutive patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Response Relationsh | 2017 |
Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls.
Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Male; Prop | 2011 |
Propranolol for treatment of ulcerated infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; H | 2011 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
β-blockers for infantile hemangiomas: a single-institution experience.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Drug Monitoring; Female; | 2011 |
Propranolol as first-line treatment of head and neck hemangiomas.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Child, Preschool; Female; Head and Neck Neopla | 2011 |
Failure of propranolol in the treatment of childhood haemangiomas of the head and neck.
Topics: Adrenal Cortex Hormones; Airway Obstruction; Anti-Inflammatory Agents; Combined Modality Therapy; Co | 2011 |
Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients.
Topics: Age Factors; Cohort Studies; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangio | 2012 |
Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Feasibility Studies | 2013 |
High levels of β2-adrenoceptors are expressed in infantile capillary hemangiomas and may mediate the therapeutic effect of propranolol.
Topics: Adrenergic beta-Antagonists; Female; Gene Expression Regulation; Head and Neck Neoplasms; Hemangioma | 2012 |
[A case of propranolol therapy for infantile capillary hemangiomas of the parotis].
Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma, Capillary; Humans; Infant; | 2012 |
Propranolol for infantile haemangioma: striking effect in the first weeks.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cohort Studies; Dose-Response Relationship, Drug; | 2012 |
Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma.
Topics: Adrenergic beta-Antagonists; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumo | 2012 |
Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Analysis of Variance; Endothelium, Vascular; Enzy | 2013 |
Removal of catecholamine-secreting chemodectoma. The use of neuroleptanaesthesia, adrenergic blockade and sodium nitroprusside.
Topics: Blood Pressure; Carotid Body Tumor; Catecholamines; Epilepsy, Temporal Lobe; Head and Neck Neoplasms | 1976 |
Modulation of placental alkaline phosphatase activity and cytokeratins in human HN-1 cells by butyrate, retinoic acid, catecholamines and histamine.
Topics: Alkaline Phosphatase; Butyrates; Butyric Acid; Carcinoma, Squamous Cell; Catecholamines; Cell Divisi | 1987 |